K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene

British Journal of Cancer

Volumn 92, Issue 6, 2005, Pages 1098-1103

  Hachisuga, T ^a   Tsujioka, H ^a   Horiuchi, S ^a   Udou, T ^a   Emoto, M ^a   Kawarabayashi, T ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Endometrium; K ras; Menstruation; Tamoxifen; Toremifene

Indexed keywords

TAMOXIFEN; TOREMIFENE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; CYTOLOGY; DNA EXTRACTION; ENDOMETRIUM; FEMALE; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN TISSUE; MENSTRUATION; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; BREAST TUMOR; COMPARATIVE STUDY; ECHOGRAPHY; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; ONCOGENE RAS; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CODON; ENDOMETRIUM; FEMALE; GENES, RAS; HUMANS; MIDDLE AGED; MUTATION; TAMOXIFEN; TOREMIFENE;

EID: 17444397119     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602456     Document Type: Article

References (25)

1. Al-Jehani RM, Jeyarajah AR, Hagen B, Hogdall EV, Oram DH, Jacobs IJ (1998) Model for the molecular genetic diagnosis of endometrial cancer using K-ras mutation analysis. J Natl Cancer Inst 90: 540-542
2. Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, Leeuwen FE, the Comprehensive Cancer Centres' ALERT Group (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 36: 881-887
3. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, Maloney EM, Perlman JA, Ford L (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91: 1654-1662
4. Chang J, Powles TJ, Ashley SE, Gregory IRK, Dowsett M (1998) Variation in endometrial thickening in women amenorrhea on tamoxifen. Breast Cancer Res Treat 48: 81-85
5. Deligdisch L, Kalir T, Cohen CJ, Latour MD, Bouedec GL, Llorca FP (2000) Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 78: 181-196
6. Feng Z, Hu W, Chen JX, Pao A, Li H, Rom W, Hung MC, Tang MS (2002) Preferantial DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst 94: 1527-1536
7. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP)B-14. J Natl Cancer Inst 86: 527-537
8. Hachisuga T, Miyakawa T, Tsujioka H, Horiuchi S, Emoto M, Kwarabayashi T (2003) K-ras mutation in tamoxifen-related endometrial polyps. Cancer 98: 1890-1897
9. Kelly MJ, Littman SJ (2002) Etiology of the mutational spectrum of ras genes in human carcinomas. J Natl Cancer Inst 94: 1516-1517
10. Lagarda H, Catasus L, Arguelles R, Guiu XM, Prat J (2001) K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193: 193-199
11. Lax SF, Kendall B, Tashiro H, Siebos RJC, Ellenson LH (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Evidence of distinct molecular genetic pathways. Cancer 88: 814-824
12. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ (1991) Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 51: 3497-3502
13. Matsubayashi H, Watanabe H, Yamaguchi T, Ajioka Y, Nishikura K, Iwafuchi M, Yamano M, Kijima H, Saito T (1999) Multiple K-ras mutations in hyperplasia and carcinoma in cases of human pancreatic carcinoma. Jpn J Cancer Res 90: 841-848
14. Mourits MJE, Vries EGED, Willemse PHB, Hoor KAT, Hollema H, Zee AGJVD (2001) Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 97: 855-866
15. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC (1998) Effects of the antiestrogens tamoxifen, toremifene and ICI182780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552-1558
16. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignacies. J Natl Cancer Inst 87: 645-651
17. Semczuk A, Berbec H, Kostuch M, Cybulski M, Wojcierowski J, Baranowski W (1998) K-ras gene point mutations in human endometrial carcinomas: correlation with clinocopathological features and patient's outcome. J Cancer Res Clin Oncol 124: 695-700
18. Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, Grollman AP, Pearl M (2000a) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21: 1461-1467
19. Shibutani S, Ravindernath A, Terashima I, Suzuki N, Laxmi YRS, Kanno Y, Suzuki M, Apak TI, Sheng JJ, Duffel MW (2001) Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Cancer Res 61: 3925-3931
20. Shibutani S, Reardon JT, Suzuki N, Sancar A (2000b) Excision of tamoxifen-DNA adducts by the human nucleotide excicion repair system. Caner Res 60: 2607-2610
21. Sun H, Enomoto T, Shroyer KR, Ozaki K, Fujita M, Ueda Y, Nakashima R, Kuragaki C, Ueda G, Murata Y (2002) Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diagn Mol Pathol 11: 204-211
22. Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori Y, Omata M (2002a) Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: Clinical utility for diagnosis of pancreatic tumor. Am J Gastroenterol 97: 2263-2270
23. Tada M, Tateishi K, Kawabe T, Sasahira N, Isayama H, Komatsu Y, Shiratori Y, Omata M (2002b) Quantity of mutant K-ras gene in pancreatic secretions for diagnosis of pancreatic carcinoma with different assays: analysis of 100 patients. Clin Chim Acta 324: 105-111
24. 2-Deoxyguaanosinyl) tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59: 2091-2095
25. Tomas E, Kaupplia A, Blanco G, Apaja-Sarkkinen M, Laatikainen T (1995) Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59: 261-266